Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) released its earnings results on Monday. The company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87), Zacks reports.
Monopar Therapeutics Price Performance
NASDAQ MNPR traded down $4.59 during mid-day trading on Friday, reaching $30.00. The stock had a trading volume of 42,416 shares, compared to its average volume of 360,003. The stock has a market cap of $183.39 million, a PE ratio of -15.23 and a beta of 1.01. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The company has a fifty day moving average price of $38.29 and a 200 day moving average price of $25.03.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on MNPR. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $44.00.
View Our Latest Report on MNPR
Insider Buying and Selling at Monopar Therapeutics
In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now owns 822,255 shares of the company's stock, valued at $28,778,925. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 34.90% of the company's stock.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Further Reading
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
